
This episode delivers a deep, unfiltered breakdown of the latest Retatrutide data—showing weight-loss results that approach and even rival bariatric surgery—while exposing the growing battle over access, pricing, and Lilly’s push to classify the drug as a biologic. It also examines the exploding gray market, new telehealth outcomes, and why the future of obesity medicine will depend on protecting patient access to these life-changing treatments.
Subscribe to your favorite podcasts and get free AI summaries within minutes of release.
Browse trending podcasts or search for your favorites
One click to follow any show — always free, no credit card
Free AI summaries delivered by email within minutes of release
Free forever · No credit card · Unsubscribe anytime
Never miss an episode of On The Pen With Dave Knapp. Subscribe for free →
No transcript available.